$18.19
-0.22 (-1.21%)
Open$18.52
Previous Close$18.41
Day High$19.26
Day Low$16.84
52W High$45.50
52W Low$0.79
Volume—
Avg Volume309.7K
Market Cap15.61M
P/E Ratio—
EPS$-9.11
SectorBiotechnology
Analyst Ratings
Sell
8 analysts
Price Target
+120.7% upside
Current
$18.19
$18.19
Target
$40.14
$40.14
$31.69
$40.14 avg
$63.06
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 548.9K | 523.5K | 509.5K |
| Net Income | 128.1K | 108.5K | 123.6K |
| Profit Margin | 23.3% | 20.7% | 24.3% |
| EBITDA | 177.1K | 173.7K | 174.5K |
| Free Cash Flow | 145.7K | 139.2K | 108.0K |
| Rev Growth | +23.9% | +19.4% | -4.0% |
| Debt/Equity | 0.65 | 0.64 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |